Keywords: Nycomed, First-quarter 2010 results
Nycomed’s 1st-qtr 2010 sales fall 7.6% and EBITDA slumps 24%, impacted by pantoprazole patent expiry
Article | 11 May 2010
Swiss privately-held drugmaker Nycomed posted a first-quarter 2010 decline in sales, to 776.4 million euros ($982.1 million), with adjusted EBITDA decreasing 24.1% (-24.8% in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
